Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial

Autor: Andrés Cervantes, H.P. Knol, L. Østergaard, M.L. Lydrup, S.A. Radema, R.F. Schmitz, P. Nieboer, J. Hol, I. Edhemovic, K.C.M.J. Peeters, A. Johnsson, F.J.F. Jeurissen, Pieter J. Tanis, A.C.M. van de Luijtgaarden, P. Quarles an Ufford, H. Kim, Hein Putter, W.A. Bleeker, Tone Fokstuen, M E van Leerdam, K. Kovacs, A. Pronk, E.D. Kerver, L.G.H. Dewit, E. Garcia Granero, P.A. Nijenhuis, T. Fokstuen, S. Ottosson, P. Flygare, M.J. Safont, Iris D. Nagtegaal, F. Svendsen Jensen, C. Bratthäll, H.M. Ceha, L. Malmberg, P. Hede, W.M. van der Deure, G. Carlsson, J. Haux, Derk Jan A. de Groot, Esmée A Dijkstra, Renu R. Bahadoer, G.A.P. Nieuwenhuijzen, B. de Valk, B. Lindh, D. Hess, G.L. Beets, J.C. Bernal, A.M.E. Bruynzeel, R.M.P.H. Crolla, C. Kersten, P. Pfeiffer, S. Biondo, M.L. Silviera, Jannet C. Beukema, W.H. Schreurs, O. Hallböök, B.L. Lödén, A. Espí Macías, V. Velenik, L. Österlund, A. Slot, Geke A. P. Hospers, H. de Wilt, A.W.K.S. Marinelli, O. Lundberg, C. Radu, J. die Trill, I. Verbiené, P. Matthiessen, Mathijs P. Hendriks, J.H.M. Bekker, M. Walldén, V. Pachón, H.W. Kapiteijn, J.M. Immink, A. Piwowar, R. Salazar, L. Påhlman, P. Braam, K.E.J. Jensen, S. Festen, O. Mjåland, Elma Meershoek-Klein Kranenbarg, Jaume Capdevila, U. Palenius, K. Villmann, J.J. van der Vliet, Albert J. ten Tije, A. Berglund, Corrie A.M. Marijnen, G. Dafnis, J. Assarsson, J. Capdevila, J.W.T. Dekker, M. Grønlie Guren, G.J. Veldhuis, Q.A.J. Eijsbouts, G.J. Creemers, J.B. Tuynman, C.J.A. Punt, P.H.J.M. Veldman, J. Aparicio, Klaas Havenga, E.D. Geijsen, W.H. Steup, T. Rozema, K. Smedh, Lennart Blomqvist, J. de Boer, Cornelis J.H. van de Velde, S. Jangmalm, J.W.P. Vanstiphout, T.C. Stam, A.C.M. van den Bergh, Annet G H Roodvoets, Janet R. Vos, E.J.M. Siemerink, R.J.I. Bosker, Bengt Glimelius, A. Cervantes, E. Espin, Per Nilsson, A.J. Ten Tije, Ibrahim Edhemovic, Boudewijn van Etten, M. Tascilar, A.N. Nesbakken, G.A. Patijn, O. Reerink, Regina G. H. Beets-Tan, S. Skullman, H. Hörberg, P. Parinkh, G. Svaninger, M.B. Polée, D. Ten Bokkel Huinink, C. Hoff, A.F.T. Olieman, H. van den Berg, F.P. Peters, Torbjörn Holm, J.M. van Rooijen, M.P. Hendriks, J. Benedik, J.H. Svensson, A.L.T. Imholz

Publikováno v: Lancet Oncology, 22, 29-42
Lancet Oncology, 22(1), 29-42. ELSEVIER SCIENCE INC
the RAPIDO collaborative investigators 2021, ' Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial ', The Lancet Oncology, vol. 22, no. 1, pp. 29-42 . https://doi.org/10.1016/S1470-2045(20)30555-6
The Lancet Oncology, 22(1), 29-42. ELSEVIER SCIENCE INC
The Lancet. Oncology
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Lancet Oncology, 22, 1, pp. 29-42
The Lancet Oncology, 22(1), 29-42. ELSEVIER
The Lancet Oncology, 22(1), 29-42. Lancet Publishing Group
lancet oncology, 22(1), 29-42. Lancet Publishing Group

BACKGROUND: Systemic relapses remain a major problem in locally advanced rectal cancer. Using short-course radiotherapy followed by chemotherapy and delayed surgery, the Rectal cancer And Preoperative Induction therapy followed by Dedicated Operation

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81d055e24de581f7d953a2dafec480d7
https://doi.org/10.1016/s1470-2045(20)30555-6

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A blinded placebo (P)-controlled phase I/II dose-escalation study (DES) of brivanib (B), an oral selective dual inhibitor of FGF and VEGF signaling, in combination with cetuximab (C) and irinotecan (I) in patients (pts) with KRAS wild-type (KWT) advanced or metastatic colorectal cancer (amCRC): Safety, tolerability, and pharmacokinetics (PK) findings

Autor: A. C. Gracian, Y. Park, P. Pfeifer, T. Fokstuen, D. Amadori, D. S. Nuyten, J. Chemidlin, M. Chacon, Anthony B. El-Khoueiry, Georgia Kollia

Publikováno v: Journal of Clinical Oncology. 28:e13552-e13552

e13552 Background: B has therapeutic potential in a variety of tumors. B+C treatment is currently being tested in phase III in refractory amCRC. An innovative phase I design was used to separate specific B toxicity (thrombosis-related events [TRE]) f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3e52f8e287ce296c2bfae99713376d7b
https://doi.org/10.1200/jco.2010.28.15_suppl.e13552

Clinical Trials and Treatment with Psychopharmaceuticals

Autor: T. Fokstuen

Publikováno v: International Pharmacopsychiatry. 5:2-15

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4250c4581c5615fbaf01f5f78b22b417
https://doi.org/10.1159/000468075

[Resources in psychiatric after care strengthened in Kronoberg county]

Autor: T, Fokstuen

Publikováno v: Tidskrift for Sveriges sjukskoterskor. 37(12)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::cfb30118e74c2cbf2f635378030fbfbc
https://pubmed.ncbi.nlm.nih.gov/4317230